体重指数下降与阿尔茨海默病病理生理学有明显的关联 APOE ɛ4 携带者和非携带者
1Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
Journal of Alzheimer's disease : JAD
|October 16, 2023
概括
追踪老年人身体质量指数 (BMI) 变化是很重要的. 较快的BMI下降与阿尔茨海默病的增加相关.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 老年学是一门学科.
背景情况:
- 体重指数 (BMI) 的变化可能与阿尔茨海默病 (AD) 病理学有关.
- 阿波利波蛋白E ɛ4 (APOE ɛ4) 等位基因对这种关联的影响仍然不清楚.
研究的目的:
- 调查BMI变化与AD病理之间的关系.
- 根据APOE ɛ4运营商身份区分这些协会.
主要方法:
- 来自阿尔茨海默病神经成像计划 (ADNI) 的862名非痴呆症参与者的分析,至少有两次BMI测量.
- 研究了BMI斜率与粉样β (Aβ) 积累,神经退行,认知和沉积的纵向变化之间的关联.
- 根据Aβ和APOE ɛ4状态进行分层分析.
主要成果:
- 在具有粉样β斑并没有APOE ɛ4等位基因的个体中,更快的BMI下降与Aβ积累增加,大脑低代谢,记忆力下降和执行功能障碍有关.
- 在没有粉样β斑块的个体中,更快的BMI下降与APOE ɛ4载体中更快的Aβ积累相关.
- 较快的BMI下降与认知能力 (记忆和执行功能) 的下降有关,无论是APOE ɛ4载体还是没有粉样β斑块的非载体.
结论:
- 体重的波动,特别是体重的下降,与阿尔茨海默病的进展有很大关系.
- APOE ɛ4基因型调节了BMI变化与AD生物标志物和认知衰退之间的关系.
- 在老年人中监测BMI为AD风险和进展提供了宝贵的见解,特别是在考虑遗传因素时.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
